Wikipedia -WSS

Wikipedia

author：explore 2025-10-02 14:22:47 - browse：2

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Scientists successfully use ultrasound imaging to map brain activity

WSS

Prosthetic arm enables patients to feel the objects they grip

U.K. considers world's first use of meningitis vaccine to address gonorrhea

David Sabatini, ex

Morphosys mixed study results for blood cancer drug

FDA's Woodcock to retire early next year

U.K. considers world's first use of meningitis vaccine to address gonorrhea

leisure time

Wikipedia

entertainment

Bright Health sells Medicare Advantage business to Molina

Heat waves linked to early deliveries, preterm births in new study

Medicare details structure of new drug price negotiation program

AI used to predict Covid

Apple is now the first public company to be valued at $3 trillion

Weight loss drug costs may need more research, senator suggests

Virginia high school admissions case could be legal follow

Stigma and the return of syphilis

Activists slam private health insurers over coverage restrictions

PBM reforms clear House panel

hotspot

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

PBM reforms clear House panel

In key trial, Verve's treatment lowers cholesterol levels in patients

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

FDA's Woodcock to retire early next year

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

focus

entertainment

leisure time

hotspot